Latest Posts › UK

Share:

The National Security and Investment Act 2021: A Snapshot of experience so far

The UK’s new national security screening tool has been in force for over 9 months and its impact on deal making is being felt. Determining whether notification is required can be complex and while the notification process...more

Pfizer and Flynn Pharma fined GBP70m for excessive and unfair pricing after UK antitrust reassessment

The UK Competition and Markets Authority (CMA) has reimposed fines on Pfizer and Flynn Pharma for abusing their dominant positions by charging excessive and unfair prices for phenytoin, an anti-epilepsy drug. ...more

The National Security and Investment Act 2021: The first market guidance notes

The UK National Security and Investment Act 2021 (NSIA) has been in force for over six months. We know that within the first three months, the UK government received 221 notifications and “called-in” 17 deals for a more...more

New UK pro-competition digital markets regime confirmed by Government

UK competition rules are facing unprecedented levels of change. Last month we reported on the UK Government’s intentions for broad reforms to the competition and consumer law regimes. Now, the Government has set out the...more

UK Government confirms reforms to competition and consumer laws

Following a consultation in summer 2021, which set out a suite of wide-ranging proposals for reforms to UK competition and consumer laws, the UK Government has now confirmed the changes that it plans to take forward. ...more

CMA consults on draft guidelines on vertical agreements

The UK Competition and Markets Authority (CMA) has published for consultation its much-anticipated draft guidance on vertical agreements (Draft Guidance). ...more

The UK Competition and Markets Authority imposes record fines for excessive pricing and anti-competitive “pay-for-delay”...

The UK Competition and Markets Authority (CMA) has imposed over GBP260 million in fines on several drug makers for two breaches of competition law: (i) charging excessive and unfair prices, in breach of the Chapter II...more

32 Results
 / 
View per page
Page: of 2

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide